<DOC>
	<DOCNO>NCT00001269</DOCNO>
	<brief_summary>This phase I study determine maximal tolerate dose IL-3 give alone sequentially GM-CSF follow FLAC chemotherapy metastatic breast cancer patient .</brief_summary>
	<brief_title>Phase I Trial FLAC ( 5-Fluorouracil , Leucovorin , Adriamycin , Cytoxan ) Plus GM-CSF ( Granulocyte-Macrophage Colony Stimulating Factor ) Plus Dose Escalation IL-3 ( Interleukin-3 ) Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase I study determine maximal tolerate dose IL-3 give alone sequentially GM-CSF follow FLAC chemotherapy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients Stage IV ( metastatic ) breast cancer eligible histologicallyproven diagnosis . Measurable disease prerequisite . Patients Stage III disease Stage 7 node positive eligible . Patients prior adjuvant chemotherapy and/or hormonal therapy eligible provide regimen include adriamycin . Patients prior radiation therapy may eligible provide extensive radiation cardiac area great 20 % bone marrow . Patients receive great 360mg/m2 adriamycin adjuvant therapy ineligible . Patient must previously untreated chemotherapy metastatic disease . There must history previous malignancy except cured nonmelanoma skin cancer ( basal squamous cell carcinoma ) , cervical cancer situ , past malignancy inactive 5 year . Performance status ( Karnofsky scale ) must great 70 ; ECOG 02 . Absolute granulocyte count great 1500/mm3 platelet count great 100,000/mm3 . Liver function test ( SCOT , Alk , Phosph. , T. Bili ) less 1.5 time upper limit normal . Serum creatinine le 1.7 creatinine clearance great 45 ml/min unless abnormality due tumor involvement . The patient must able give informed consent , return NCI treatment adequate followup period protocol require . No pregnant patient may enter study ; patient inform need contraception . Patients must great equal 18 year age . No patient poor medical psychiatric risk nonmalignant systemic disease would preclude subjected treatment protocol . No patient history cardiac disease must normal ejection fraction MUGA Scan angina . Patients receive prior adriamycin must LVEF great 45 % . No history CNS metastasis , know seizure disorder . No allergy study medication . No pregnant lactacting woman . No patient require ongoing therapy asthma . No patient bleed disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Dose-Intensive Chemotherapy</keyword>
	<keyword>Hematopoietic Growth Factor</keyword>
	<keyword>Peripheral Blood Progenitor Cell</keyword>
</DOC>